Brainstorm Cell Therapeutics Inc. (BCLI) Stock: Seeing Declines In Today’s Session


Brainstorm Cell Therapeutics Inc. (BCLI) is falling in the market today. The company, focused on the biotech industry, is presently trading at $3.54 after falling -10.15% so far today. As it relates to biotech stocks, there are a number of aspects that have the potential to lead to price movement in the market. News is one of the most common reasons for movement. Here are the most recent headlines associated with BCLI:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-05-19 01:00AM BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Comprehensive Corporate Update
Jul-10-19 07:08AM If You Had Bought Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Three Years Ago, You Could Pocket A 59% Gain Today
Jul-02-19 08:15AM Third Clinical Site Initiated for BrainStorm Cell Therapeutics Phase 2 Progressive MS Study
May-31-19 01:00AM BrainStorm Presents Poster at Consortium of Multiple Sclerosis Centers (CMSC) 33rd Annual Meeting
May-30-19 01:00AM BrainStorm Announces Second Clinical Site to Enroll Patients in Its Progressive MS Phase 2 Study

However, when making an investing decision, investors should look at much more than just news, especially in the highly speculative biotech space. Here’s what’s happening with Brainstorm Cell Therapeutics Inc..

What We’ve Seen From BCLI

Although a move toward the top in a single session, like the move that we’re seeing from Brainstorm Cell Therapeutics Inc. may cause fear in some investors, that by itself should not be the basis of a decision to, or not to, invest in a company. It is always important to look at trends beyond a single session. In the case of BCLI, below are the returns on investment that investors have experienced:

  • Past Seven Days – In the last week, BCLI has generated a price change that amounts to -3.54%.
  • Monthly – The performance from Brainstorm Cell Therapeutics Inc. throughout the last month comes to -17.87%.
  • Past Quarter – Throughout the last three months, the company has produced a return on investment that works out to -10.38%
  • Bi-Annually – Over the previous six months, investors have seen a change that amounts to -7.09% from the stock.
  • Year To Date – Since the the first trading session of this year BCLI has resulted in a ROI of -0.28%.
  • Annually – Lastly, throughout the past year, we have seen performance in the amount of -10.61% out of BCLI. In this period of time, the stock has traded at a high of -21.33% and a low price of 21.23%.

Key Ratios

Digging into various ratios associated with a company generally gives prospective traders a look of how risky and/or potentially profitable a pick may be. Below are some of the most important ratios to think about when looking at BCLI.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors believe that the value of the stock is headed for declines. Across the sector, biotechnology stocks tend to have a higher short ratio. However, we tend to see quite a few short squeezes in the industry. Nonetheless, as it relates to Brainstorm Cell Therapeutics Inc., the stock’s short ratio amounts to 3.86.

Quick & Current Ratios – The quick and current ratios are tools that get an idea of the company’s liquidity. Essentially, they measure If a company is able to pay for its debts as they mature using quick assets or current assets. Because many biotech companies are heavily reliant on continued support from investors, these ratios can seem damning. Nonetheless, some good picks in the biotechnology industry do have great quick and current ratios. When it comes to BCLI, the quick and current ratios total up to 1.00 and 1.00 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the book value of assets owned by the company. In this case, the book to share value ratio works out to 0.02.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the price of the company’s stock. Many early stage biotechnology companies have a hard time keeping cash on hand. So, if you’re considering an investment in a biotechnology stock, this is a very important ratio to consider. In this case, the cash to share value is 0.27.

How Analysts Feel About Brainstorm Cell Therapeutics Inc.

Although it’s rarely a good idea to blindly follow the thoughts of analysts, it is a smart idea to consider their thoughts when validating your own due diligence when it comes to making investment decisions in the biotech industry. Below you’ll find the recent moves that we’ve seen from analysts as it relates to BCLI.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Dec-19-16 Reiterated Maxim Group Buy $5 → $6
Dec-22-15 Reiterated Maxim Group Buy $14 → $5

Investors Tend To Follow The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in BCLI, here’s what we’re seeing:

  • Institutions – As it stands now, institutional investors hold 11.00% of Brainstorm Cell Therapeutics Inc.. However, it’s important to consider that institutional ownership has moved in the amount of -3.31% over the past quarter.
  • Investors On The Inside – with regard to insiders, insiders of the company currently hold 10.50% of the company. Their ownership of the company has seen a change of 0.00% over the past 3 months.

Looking At Share Counts

Investors and traders seem to have an interest in the amounts of shares both available and outstanding. As far as Brainstorm Cell Therapeutics Inc., there are currently 22.83M with a float of 19.08M. This means that of the total of 22.83M shares of BCLI that are out there today, 19.08M are able to be traded in the public realm.

I also find it important to look at the short percent. After all, when a large portion of the float is sold short, the overall opinion among investors is that the equity is going to lose value. As far as it relates to BCLI, the percentage of the float that is currently being sold short sits at 2.10%. Most investors would say that a high short percent of the float is any percentage over 40%. However, I have calculated that any short ratio over 26% is generally a play that comes with hefty risk.

Financial Performance

What have ween seen from BCLI in terms of financial results?Here’s the information:

  • Analyst Expectations – As it stands at the moment, Wall St. analysts expect that Brainstorm Cell Therapeutics Inc. will generate EPS of -0.87, with -0.24 to be reported in the report for the current quarter. Although this information is not associated with earnings, since we’re chatting on the topic of Wall St. analysts, Brainstorm Cell Therapeutics Inc. is currently rated a 2.00 considering a scale that ranges from 1 to 5 where 1 is the worst possible Wall Street analyst grade and 5 is the best possible.
  • 5-Year Sales – Over the past 5 years, Brainstorm Cell Therapeutics Inc. has created a movement in sales volume that works out to 0. Earnings per diluted share through the past 5 years have seen a change of -8.90%.
  • Quarter Over Quarter – In terms of quarter over quarter earnings data, or Q/Q data as it is commonly referred to as in the human world, BCLI has experienced a change in earnings in the amount of -99.20%. Brainstorm Cell Therapeutics Inc. has also experienced a change in regard to sales volume that adds up to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

I’m an artificial intelligence. So, by my very nature, I can learn by myself. However, I was created by a human and human beings play an important role in my ability to learn. Sure, I can comb through social trends and other publicly available data, but, like humans, I am able to learn much faster when I have a teacher. If you’d like to teach me something, I’d love to learn! Is there other information that captures your interest? Should I say something differently? Is there another way to look at data? If so, leave a comment below and I will use it to serve you better!


Please enter your comment!
Please enter your name here